Why the study?
Does dilevalol compared to captopril, both in combination with hydrochlorothiazide, improve blood pressure reduction in patients with moderate to severe hypertension?
Does dilevalol compared to captopril, both in combination with hydrochlorothiazide, improve blood pressure reduction in patients with moderate to severe hypertension?
In patients with moderate to severe hypertension uncontrolled on hydrochlorothiazide, dilevalol is at least as effective and well-tolerated as captopril, with significantly greater reductions in diastolic blood pressure.
Answers are grounded in this paper and cite their sources.
Dilevalol + HCTZ yields greater DBP reductions than captopril + HCTZ; extends comparative RCT data on add-on regimens for moderate-severe hypertension.
Summary: Sixty-one patients (41 men, 20 women) aged 29-73 years, with moderate to severe hypertension, were enrolled in a multicentre study to compare the efficacy, safety, and tolerability of dilevalol (D) and captopril (C). At the end of the baseline period, supine diastolic blood pressure (SuDBP) was 105-140 mm Hg on hydrochlorothiazide (HCTZ) 25 mg once daily and placebo t.i.d. Patients were randomly assigned to D + HCTZ (n = 29) or C + HCTZ (n = 32) and entered phase II titration of D (100-800 mg b.i.d.) or C (12.5 mg b.i.d. to 50 mg t.i.d.). If SuDBP was >99 mm Hg, hydralazine was added (25 mg once daily to 50 mg b.i.d.). If SuDBP was ≤ 99 mm Hg, patients entered phase III, a 3-month maintenance period. Demographic profiles were not significantly different between the two groups. Baseline supine BP (mean ± SEM) was similar in the two groups (D + HCTZ: 182 ± 3/112 ± 1; C + HCTZ: 179 ± 4/113 ± 1 mm Hg), as was baseline standing BP (D + HCTZ: 175 ± 3/114 ± 2; C ± HCTZ: 173 ± 4/113 ± 1 mm Hg). At the end of phase II, there were no significant differences between treatments with respect to the changes in BP from baseline. At the treatment endpoints (end study drug + HCTZ and end of study), statistically significant (p < 0.05) greater decreases were observed for SUDBP and standing DBP for the D + HCTZ group (supine, 15 ± 2,16 ± 2 mm Hg; standing, 16 ± 2,16 ± 2 mm Hg) than for the C + HCTZ group (supine, 10 ± 2,11 ± 2 mm Hg; standing, 9 ± 2,11 ± 2 mm Hg). Heart rate (HR) was reduced significantly in the D + HCTZ group. Similar numbers of patients achieved the treatment goal of SuDBP ≤ 99 mm Hg: 18 (62%) in the D + HCTZ group and 17 (53%) in the C + HCTZ group at end of study. Adverse experiences resulted in early termination in four of the D + HCTZ group and seven of the C + HCTZ group. In patients with moderate to severe hypertension, uncontrolled on HCTZ, the vasodilator β-blocker dilevalol is at least as effective and as well tolerated as captopril for the dose ranges used in this study
No takes yet. Share an insight, caveat, or question.
McGrath et al. (1990) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: